Carasent AB (publ)APXZF 80 PB Ratio is 0.12 as of Jun. 29, 2026, which is 95% below its 10-year median of 2.23. GuruFocus rates APXZF with a GF Score™ of 80/100 and a GF Value™ of $0.18. The stock has 3 warning signs investors should review. Among 608 Healthcare Providers & Services companies, Carasent AB (publ) ranks better than 50.82% on this metric.
Carasent AB (publ) stock PB Ratio (=1.96) is close to 1-year low of 1.89.
The historical rank and industry rank for Carasent AB (publ)'s PB Ratio or its related term are showing as below:
APXZF'
s PB Ratio Range Over the Past 10 Years
Min: 0.71 Med: 2.23 Max: 5.85
Current: 1.96
During the past 13 years, Carasent AB (publ)'s highest PB Ratio was 5.85. The lowest was 0.71. And the median was 2.23.
APXZF's PB Ratio is ranked better than 50.82% of 608
companies
in the Healthcare Providers & Services industry
Industry Median: 1.985
vs APXZF: 1.96
During the past 12 months, Carasent AB (publ)'s average Book Value Per Share Growth Rate was -4.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -10.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 5.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 23.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Carasent AB (publ) was 90.30% per year. The lowest was -36.90% per year. And the median was -3.60% per year.
Back to Basics: PB Ratio
Carasent AB (publ) (OTCPK:APXZF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Carasent AB (publ) PB Ratio Related Terms
Carasent AB (publ) PB Ratio Historical Data
* Premium members only.
The historical data trend for Carasent AB (publ)'s PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Carasent AB (publ)'s PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s PB Ratio distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Carasent AB (publ) (APXZF) has a PB Ratio of 0.12 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Carasent AB (publ) and its competitors. This is 95% below median its historical median of 2.23. Over the past decade, Carasent AB (publ)'s PB Ratio has ranged from 0.71 to 5.85. According to the industry distribution chart, Carasent AB (publ) ranks #299 out of 608 companies in the Healthcare Providers & Services industry, placing it in the top 49.2%.
Is Carasent AB (publ)'s PB Ratio too high?
Carasent AB (publ)'s current PB Ratio of 0.12 is 95% below median its 10-year median of 2.23. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 5.85. The Healthcare Providers & Services industry median PB Ratio is 1.99. Carasent AB (publ)'s value of 0.12 is 94% below this industry median. Based on the distribution chart, Carasent AB (publ) ranks #299 out of 608 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Carasent AB (publ) has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s PB Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #299 out of 608 companies for PB Ratio. This puts Carasent AB (publ) in the upper half of its industry. The industry median PB Ratio is 1.99. Carasent AB (publ)'s value of 0.12 is 94% below this benchmark. Historically, Carasent AB (publ)'s own PB Ratio has ranged from 0.71 to 5.85 over the past decade. While the company's 10-year median is 2.23 vs. the industry median of 1.99, Carasent AB (publ) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 1.99, based on 608 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carasent AB (publ)'s current PB Ratio of 0.12 is 94% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Carasent AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current PB Ratio is 0.12, which is 95% below median its own 10-year median of 2.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (APXZF) has a current PB Ratio of 0.12. The stock's GF Value™ is $0.18, compared to a current price of $0.15 — trading 16.7% below its estimated fair value. The current PB Ratio is 0.12, which is 95% below median its 10-year median of 2.23 and 94% below the Healthcare Providers & Services industry median of 1.99. Carasent AB (publ)'s overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Carasent AB (publ) (APXZF), the current PB Ratio is 0.12 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (APXZF) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of $0.15 is trading 16.7% below its estimated GF Value™ of $0.18.
Key valuation signals for APXZF:
PB Ratio: 0.12 (95% below median its 10-year median of 2.23)
GF Value™: $0.18 vs. price of $0.15 (16.7% below fair value)
Industry Position: 94% below the Healthcare Providers & Services median (#299 of 608)
No single metric tells the full story. See the APXZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
80GF Score
Get the complete analysis for APXZF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APXZF has been successfully added to your 
